Patents by Inventor Gildas Le Gal la Salle

Gildas Le Gal la Salle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain
    Patent number: 6756523
    Abstract: The invention concerns a recombinant DNA vector characterized in that it is capable of directing the expression an/or transcription of a selected nucleotide sequence in the cells of the central nervous system and in that it comprises (i) at least part of the genome of an adenovirus, including the regions required for that adenovirus to penetrate into the cells normally infectable by that adenovirus and (ii) being inserted into said part of genome of an adenovirus under the control of a promoter, either present or also inserted into said genome part and operative in said cells. This recombinant vector finds particular use in the treatment of diseases of the central nervous system, also in gene therapy.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 29, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Axel Kahn, Gildas Le Gal La Salle, Jacques Mallet, Michel Perricaudet, Marc Peschanski, Jean-Jacques Robert
  • Assays for promoter operability in central nervous system cells
    Patent number: 6458529
    Abstract: The invention concerns a recombinant DNA vector characterized in that it is capable of directing the expression an/or transcription of a selected nucleotide sequence in the cells of the central nervous system and in that it comprises (i) at least part of the genome of an adenovirus, including the regions required for that adenovirus to penetrate into the cells normally infectable by that adenovirus and (ii) being inserted into said part of genome of an adenovirus under the control of a promoter, either present or also inserted into said genome part and operative in said cells. This recombinant vector finds particular use in the treatment of diseases of the central nervous system, also in gene therapy.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: October 1, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Axel Kahn, Gildas Le Gal la Salle, Jacques Mallet, Michel Perricaudet, Marc Peschanski, Jean-Jacques Robert